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Metabolic phenotype-microRNA data fusion analysis of the
systemic consequences of Roux-en-Y gastric bypass surgery
Q Wu1,6, JV Li1,2,6, F Seyfried3, CW le Roux4,5, H Ashraﬁan1, T Athanasiou1, W Fenske3, A Darzi1, JK Nicholson1,2, E Holmes1,2 and
NJ Gooderham1
BACKGROUND/OBJECTIVES: Bariatric surgery offers sustained marked weight loss and often remission of type 2 diabetes, yet the
mechanisms of establishment of these health beneﬁts are not clear.
SUBJECTS/METHODS: We mapped the coordinated systemic responses of gut hormones, the circulating miRNAome and the
metabolome in a rat model of Roux-en-Y gastric bypass (RYGB) surgery.
RESULTS: The response of circulating microRNAs (miRNAs) to RYGB was striking and selective. Analysis of 14 signiﬁcantly altered
circulating miRNAs within a pathway context was suggestive of modulation of signaling pathways including G protein signaling,
neurodegeneration, inﬂammation, and growth and apoptosis responses. Concomitant alterations in the metabolome indicated
increased glucose transport, accelerated glycolysis and inhibited gluconeogenesis in the liver. Of particular signiﬁcance, we show
signiﬁcantly decreased circulating miRNA-122 levels and a more modest decline in hepatic levels, following surgery. In mechanistic
studies, manipulation of miRNA-122 levels in a cell model induced changes in the activity of key enzymes involved in hepatic energy
metabolism, glucose transport, glycolysis, tricarboxylic acid cycle, pentose phosphate shunt, fatty-acid oxidation and gluconeogenesis,
consistent with the ﬁndings of the in vivo surgery-mediated responses, indicating the powerful homeostatic activity of the miRNAs.
CONCLUSIONS: The close association between energy metabolism, neuronal signaling and gut microbial metabolites derived from
the circulating miRNA, plasma, urine and liver metabolite and gut hormone correlations further supports an enhanced gut-brain
signaling, which we suggest is hormonally mediated by both traditional gut hormones and miRNAs. This transomic approach to
map the crosstalk between the circulating miRNAome and metabolome offers opportunities to understand complex systems
biology within a disease and interventional treatment setting.
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INTRODUCTION
Obesity and its comorbidities have reached epidemic proportions
across the developed and developing world, imposing an
unsustainable socioeconomic burden on many societies.1 Bariatric
surgery is the most effective treatment strategy for morbidly
obese patients (body mass index 440 kgm−2), or those with
obesity comorbidities at a lower body mass index, as it can
achieve sustained long-term weight loss and place type 2 diabetes
in remission within days.2 Unlike diet-induced weight loss, Roux-
en-Y gastric bypass (RYGB) achieves substantial weight loss with
enhanced satiety, decreased hunger and increased energy
expenditure while food restriction and malabsorption have not
been identiﬁed as major players, in addition to reduced food
intake.3 However, although the anatomical rearrangement leads
to enterohormonal changes, altered bile ﬂow4 profound changes
of the gut microbiota5,6 and downregulation of endocannabinoids,7
the mechanism by which RYGB modulates metabolic pathways in
an integrated way and the molecules responsible for coordinating
these effects remain largely unknown.
MicroRNAs (miRNAs) are non-coding RNAs, 18–25 nucleotides in
length, which regulate thousands of genes at the post-
transcriptional level;8 each miRNA can potentially target multiple
mRNAs. This multi-targeting feature of miRNAs deﬁnes their
unique role in governing multiple metabolic processes simulta-
neously. With their ability to inﬂuence pathway networks and high
expression level in cells, miRNAs are believed to confer biological
system robustness under homeostatic disturbance.9 We hypothe-
sized that following RYGB surgery, which profoundly changes
nutrients and bile ﬂow, the individual establishes a new metabolic
balance via the manipulation of miRNAs. Therefore, we proﬁled
and integrated the plasma miRNAome and metabolome from
Sprague Dawley (SD) rats undergoing RYGB surgery using a
Statistical HeterospectroscopY (SHY) method,10 aiming to probe
the composition of circulating miRNAs, which could behave as
master metabolic regulators mediating post RYGB biological
effects. Subsequent downstream in vitro model was used to
probe these miRNA-mediated metabolic pathway alterations post
RYGB surgery.
MATERIALS AND METHODS
Experiment design and sample collection
The animal experiment was carried out under a UK home ofﬁce licence (PL
70-6669). Thirteen male SD rats were individually housed and kept under a
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12 h/12 h light/dark cycle at room temperature. All rats were acclimatized
and fed high-fat diet for 1 week prior to the experiment. Animals were
randomly divided into two groups: RYGB (n= 8) and SHAM (n=5). The
antibiotic combination amoxicillin/ﬂucoxacillin was administrated pre-
surgery to all rats at a dose of 12.5 mg per rat.
Animal body weight (BW) and food intake were measured daily. The gut
hormones (for example, peptide YY (PYY) and glucagon-like peptide 1
(GLP-1)) were measured on the day of killing. Blood was collected from all
groups in the fasting state via cardiac puncture under terminal anesthesia
in tubes containing EDTA and dipeptidyl peptidase-4 inhibitor. The plasma
fraction was separated by centrifugation at 4 °C and stored at − 80 oC. All
samples were assayed in duplicate. PYY-like inmmunoactivity was
measured with a speciﬁc and sensitive radioimmunoassay, which measure
both the full length (PYY1-36) and the fragment (PYY3-3^). GLP-1
was measured in duplicate by established in-house radioimmunoassay
(Millipore, Billerica, MA, USA).
Spot urinary samples were collected at day 52 and all rats were culled
53 days after the surgery. Approximately 5 ml of whole blood was taken
from the heart, 2.5 ml of which was transferred into an EDTA-containing
tube (BD Bioscience, Oxford, UK) and the remaining to a sodium heparin-
coated tube. After a gentle shake, they were immediately centrifuged at
3500 g at room temperature for 10min. The resulting plasma samples were
collected into two 1.5-ml RNase-free Eppendorf tubes, separately. The left
lobe of the liver was collected from each rat. All samples were immediately
snap-frozen in liquid nitrogen and stored at − 80 oC.
Sample preparation for NMR spectroscopic analyses
Plasma samples collected using sodium heparin and urine were
thoroughly defrosted and vortexed for 15 s. A total of 30 μl of urine was
mixed with 25 μl of 0.2 M sodium phosphate buffer in deuterium oxide
(0.01% of sodium 3-(trimethylsilyl) propionate-2,2,3,3-d4, pH= 7.4), and
50 μl of the mixture was transferred into a nuclear magnetic resonance
(NMR) tube with an outer diameter of 1.7 mm for further spectroscopic
analysis. A total of 400 μl of plasma was mixed with 250 μl of saline
containing 20% deuterium oxide for the magnetic ﬁeld lock. The resulting
mixture was centrifuged at 10 000 g for 10 min, and 600 μl of supernatant
was transferred into a NMR tube with an outer diameter of 5 mm pending
1H NMR spectral acquisition. The liver tissue extraction is described in SI
Materials and Methods. The dry extracts of liver aqueous phase were
resuspended in a mixture of 100 μl water, 400 μl deuterium oxide and
400 μl aforementioned sodium phosphate buffer, centrifuged for 10min at
10 000 g, and 600 μl of supernatant was transferred into a NMR tube.
1H Nuclear magnetic resonance spectroscopy of urine, plasma and
liver extracts, and spectral data analysis
1H NMR spectra of urine, plasma and liver aqueous extract samples were
obtained using a Bruker 600MHz spectrometer (Bruker; Rheinstetten,
Germany) at the operating 1H frequency of 600.13MHz with a temperature
of 300 K. A standard NMR pulse sequence (recycle delay (RD)-90o-t1-90
o-tm
-90o-acquisition) was applied to acquire one-dimensional 1H NMR spectral
data, where t1 was set to 3 μs and tm (mixing time) was set to 100ms.
Suppression of the water peak was achieved using selective irradiation
during RD of 2 s and tm. A 90 degree pulse was adjusted to ~ 10 μs. A total
of 128 scans for plasma samples and 256 scans for liver aqueous extracts
were collected into 64 k data points with a spectral width of 20 ppm.
A Carr–Purcell–Meiboom–Gill pulse sequence (RD-90°-(τ-180°-τ)n-acquisi-
tion) was applied additionally to plasma samples to better visualize the
signals of the low molecular weight metabolites. For the Carr–Purcell–
Meiboom–Gill experiment, a spin relaxation delay (2nτ) of 64 ms was used.
1H NMR spectral data processing and multivariate statistical analysis are
described in Supplementary Information Materials and Methods.
RNA isolation, reverse transcription and preampliﬁcation for
Taqman miRNA low-density array
Total RNAs in plasma and the liver homogenates were extracted using a
mirVANA PARIS RNA isolation kit (Ambion, Paisley, UK). The procedures for
the liver RNA extraction followed the manufacturer's instruction, whereas
for plasma samples, minor modiﬁcations were applied to better eliminate
plasma protein. In brief, 100 μl of the plasma sample was diluted with
100 μl cell disruption buffer and then 200 μl of 2 × denature solution was
added. The remaining extraction steps are the same as the manufacturer’s
instruction. RNAs from both plasma and liver tissues were eluted from
mirVANA PARIS columns using 100 μl of 95 oC DNase and RNase-free water
and stored at − 20 oC pending analysis.
Total RNA was reverse transcribed using Taqman Megaplex pools.
Reverse transcription (RT) mix was prepared following the manufacturer’s
instructions. RT mix (4.5 μl) was mixed with 3 μl total RNA extracted from
plasma. The RT products were preampliﬁed according to the manufac-
turer’s recommendations. RT product (2.5 μl) was combined with 12.5 μl
Taqman PreAmp Master Mix (2 × ) and 2.5 μl Megaplex PreAmp
Primers (10 × ) to generate a ﬁnal 25 μl preampliﬁcation PCR mix.
Preampliﬁcation was carried out following the manufacturer’s instructions.
Preampliﬁcation PCR product (10 μl) was diluted with 30 μl 0.1 × TE buffer
(pH 8.0). The diluted preampliﬁcation PCR product was stored at − 20 oC
until required.
Taqman miRNA low-density array
Taqman Array Rodent Card is able to detect all 373 miRNAs expressed in
rat according to the Sanger miRBase v15. Each complete assay contain two
sets of cards (Card A and B). Card A detects well-characterized miRNAs,
which tend to be function deﬁned and broadly/highly expressed. Card B
detects most of the recently discovered, less functional deﬁned and
narrowly or low-expressed miRNAs. Diluted preampliﬁcation product (9 μl)
was combined with 450 μl Taqman universal PCR Master Mix (no AmpErase
UNG, 2 × ) and 441 μl RNase/DNase-free water. Quantitative PCR reaction
mix (100 μl) was loaded into each port of the TaqMan MicroRNA Array. The
array card was centrifuged at 331 g for 2 min and then mechanically sealed
with Applied Biosystems 7900HT upgrade kit. Quantitative RT-PCR reaction
was carried out using an Applied Biosystems 7900HT thermocycler
according to the manufacturer’s recommended cycling conditions.
The single Taqman miRNA assay, mRNA target prediction, protein
extraction from the liver and Immunoblot, MiRDIAN miR-122 mimic
transfection, and statistical correlation analysis among gut hormones,
miRNAome and metabolome are described in SI Materials and Methods.
RESULTS
RYGB surgery alters gut hormone levels and metabolite proﬁles of
urine, plasma and liver extracts in SD rats
RYGB surgery induced a reduction of 22.0% of pre-surgical BW in
SD rats (n= 8) over 52 days (pre-surgery BW=467.9 ± 12.9 g, post-
surgery BW= 377.8 ± 33.9 g), whereas sham-operated animals
(n= 5) had an average BW of 573.2 g over the experimental period
(Supplementary Figure S1A). Consistent with previous studies,11 we
observed that the plasma concentrations of gut hormones, GLP-1
and PYY, were signiﬁcantly elevated following RYGB surgery
(GLP-1RYGB = 71.5 ± 11.7 pmol l
− 1, GLP-1SHAM = 10.5 ± 3.3 pmol l
− 1,
Po0.001; PYYRYGB=26.2±5.6 pmol l−1, PYYSHAM=10.4±4.8 pmol l−1,
Po0.001) (Supplementary Figures S1B and C).
Orthogonal-partial least squares-discriminant analysis (OPLS-DA) of
1H nuclear magnetic resonance (NMR) spectroscopic data of
urine, plasma and liver tissue collected 52 days post operation
showed clear postoperative shift in metabolism in all matrices
(Supplementary Figure S2, Table 1). Similar to our previous
ﬁndings in Wistar rats and C57BL6 mice, urinary concentrations of
citrate, fumarate, 2-oxoglutarate and succinate decreased post
RYGB surgery, suggesting an enhancement in tricarboxylic acid
cycle (TCA) activity.6,12 Increased urinary excretion of host-
microbial co-metabolites including indoxyl sulfate, p-cresyl sulfate,
p-cresyl glucuronide, phenylacetylglycine and trimethylamine N-
oxide were observed. RYGB reduced plasma lipids and increased
pyruvate, lactate and alanine, suggesting increased lipid metabo-
lism and glycolysis. Elevations in the concentrations of hepatic
glycogen, glucose, glycerol, lactate and alanine are consistent with
the downregulation of gluconeogenesis and an increased
conversion between glycogen and glucose. These observations
of altered hormonal and metabolic status support extant literature
and suggest that RYGB extensively regulates multiple energy
metabolism-related pathways.
RYGB modulates microRNA and metabolic proﬁles
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Table 1. Plasma, urinary and hepatic aqueous metabolites found to be altered between RYGB- and SHAM-operated rats based on OPLS-DA models
Plasma metabolite An OPLS-DA model of plasma CPMG spectral data (Q2Y = 0.83; R2X = 33.5%)
Change in RYGB Peak (ppm) P-value q-value
CH3 ↓ 0.87 0.002 0.025
(CH2)n ↓ 1.266 0.005 0.03
CH2CH2CO ↓ 1.562 0.006 0.03
CH2C=C ↓ 2.036 0.002 0.02
CH2C=O ↓ 2.227 0.004 0.03
CH=CH ↓ 5.3 0.007 0.03
Pyruvate ↑ 2.357 0.006 0.03
Lactate ↑ 4.107 0.004 0.03
D-3-hydroxybutyrate ↓ 1.178 0.09 0.14
Glutamine ↓ 2.426 0.003 0.03
Citrate ↑ 2.664 0.02 0.06
Creatine ↓ 3.023 0.004 0.03
TMAO+betain ↓ 3.252 0.004 0.03
Glycerol ↓ 3.566 o0.001 0.01
2-deoxycytidine ↓ 6.04 o0.001 0.02
Formate ↑ 8.443 o0.001 0.003
Phenylalanine ↓ 7.407 0.004 0.03
Acetate ↑ 1.904 0.03 0.06
2-phenylpropionate* ↑ 1.425 o0.001 0.005
Alanine ↑ 1.471 o0.001 0.005
Lysine ↑ 1.892 o0.001 0.006
3-aminoisobutyrate* ↑ 1.2 0.004 0.03
Urinary metabolite An OPLS-DA model of urinary spectral data (Q2Y = 0.93; R2X = 36.8%)
Change in RYGB Peak (ppm) P-value q-value
Succinate ↓ 2.413 o0.001 o0.001
2-oxoglutarate ↓ 2.448 o0.001 o0.001
Citrate ↓ 2.548 o0.001 o0.001
Fumarate ↓ 5.528 o0.001 o0.001
2-oxoadipate ↑ 1.824 o0.001 0.002
5-aminovalerate ↑ 1.645 0.05 0.06
Pimelate ↑ 1.31 0.004 0.01
TMAO ↑ 3.273 0.002 0.007
Taurine ↓ 3.433 0.002 0.006
Creatine ↑ 3.933 0.1 0.09
Creatinine ↓ 4.054 o0.001 0.003
4-hydroxyphenylacetate ↑ 3.454 0.001 0.004
Unknown ↑ 3.523 0.002 0.006
p-cresyl glucuronide ↑ 2.301 0.002 0.005
p-cresyl sulfate ↑ 2.346 0.002 0.007
PAG ↑ 3.757 o0.001 o0.001
Hippurate ↓ 3.974 0.009 0.02
Trigonelline ↓ 4.436 o0.001 o0.001
Indoxyl sulfate ↑ 7.714 o0.001 0.002
Liver metabolite An OPLS-DA model of liver aqueous extract (Q2Y = 0.81; R2X = 45.6%)
Change in RYGB Peak (ppm) P-value q-value
Lactate ↑ 1.339 0.001 0.005
Alanine ↑ 1.479 0.01 0.02
Glucose ↑ 5.238 o0.001 0.002
Glycogen ↑ 5.415 o0.001 0.002
Glycerol ↑ 3.78 o0.001 0.001
Uracil ↑ 5.803 0.03 0.05
Hypoxanthine ↑ 8.2 0.006 0.02
Abbreviations: CPMG, Carr-Purcell-Meiboom-Gill; OPLS-DA, orthogonal-partial least squares-discriminant analysis; PAG, phenylacetylglycine; RYGB, Roux-en-Y
gastric bypass; TMAO, trimethylamine-N-oxide. R2X represents the variation in 1H NMR spectral data explained by the OPLS-DA model. Q2Y indicates the level
of signiﬁcance of the metabolic differences between two classes. The P- and q-values in the table represent the signiﬁcance of the metabolite changes and
false discovery rate-adjusted P-values, respectively. The arrow up or arrow down represents the increased or decreased trend of metabolites in RYGB-operated
rats compared with SHAM controls. *Tentative metabolite assignment.
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RYGB profoundly inﬂuences the global circulating miRNA
expression in plasma
We next investigated the inﬂuence of RYGB on the circulating
miRNAome using Taqman low-density array cards. Normalization
is a key issue in circulating miRNA data analysis, thus we ﬁrst
developed a method for normalization of multiple-miRNAs and
demonstrated its superiority over the widely used spike-in
Caenorhabditis elegans cel-miR-39, global normalization and U6
normalization methods (as detailed in the Supplementary
information, Supplementary Figure S3). Raw miRNA data were
normalized using ﬁve endogenous miRNAs (U6-1, U6-2 miR-16,
miR-223 and miR-1937b), and a total of 113 and 92 plasma
circulating miRNAs were detected in four RYGB- and four SHAM-
operated rats, respectively, 88 of which were common to both
groups (Supplementary Table S1). Fourteen miRNAs were found to
be signiﬁcantly differentially expressed using a two-tailed student
t-test (Po0.05) (Figure 1a). Eleven of the altered miRNAs were
downregulated (miR-122, miR-93*, miR-872, miR-7*, miR-146a,
miR-342-3p, miR-150, miR-139, miR-30a, miR-30e, miR-320),
whereas three miRNAs, namely miR-463*, miR-34c* and miR-1188,
were upregulated in the RYGB group. The clustered miRNA
proﬁles show clear differentiation of the RYGB and SHAM groups
(Figure 1b), wherein the RYGB-altered miRNAs typically exhibited a
1.5- to sixfold change compared with sham-operated rats, with the
exception of miR-122, which demonstrated a 56-fold (P= 0.0095)
downregulation in RYGB-operated animals. This is consistent with
a previous ﬁnding in RYGB patients, where miR-122 decreased
signiﬁcantly (−94.2%, Po0.0001) when comparing baseline and
after surgery miR-122 levels.13 Therefore, our data support the
hypothesis that RYGB signiﬁcantly alters circulating miRNAs, and
thus the metabolic consequences of this require further
investigation.
RYGB-altered plasma miRNAs inﬂuence multiple inﬂammation,
obesity and neurodegenerative disease-related pathways
To gain insight into miRNA-mediated metabolic pathways affected
by RYGB surgery, we predicted the mRNA targets of each of these
altered circulating miRNAs with nine commonly used databases
(See Materials and Methods) and retained only targets predicted
by more than two programmes for further analysis. Based on the
predicted pathways ranked according to the number of dis-
criminatory miRNAs involved in each pathway (Figure 1c), we
found that signaling pathways, speciﬁcally G protein signaling,
neurodegenerative, inﬂammation, and growth and apoptosis were
highly likely to be inﬂuenced by the surgery. In particular,
miR-342-3p, miR-320, miR-139-5p and miR-146a were predicted
to be involved in multiple neurological transmitter and receptor-
related pathways, as well as two major neurodegenerative
disease-associated pathways (Parkinson’s and Huntingtons
diseases), suggesting that RYGB surgery may modulate neurolo-
gical activity through a miRNA-mediated gut-brain axis. Nine out
of these 14 RYGB-altered miRNAs are associated with Parkinson’s
disease.
Correlation between miRNAome and the metabolic phenotype
post RYGB surgery
Following the analysis of predicted miRNA-targeted pathways, we
investigated the complex correlations between the circulating
miRNAome and the plasma, urinary and hepatic metabolomes. We
found that a number of distinctive sets of miRNAs from observed
global circulating miRNAs were strongly correlated with plasma
lipids, TCA cycle intermediates, host-gut microbial co-metabolites,
liver and plasma energy metabolites (Figure 2) and gut hormones
(Supplementary Figure S4). Downregulated plasma miR-342-3p
and upregulated miR-34c* in RYGB-operated rats demonstrate a
broad correlation with the liver, plasma and urinary metabolite
proﬁles, indicating their extensive involvement in metabolic
processes. Furthermore, miR-206, miR-1188, miR-1971 and miR-
-34c* are inversely correlated with plasma lipid fractions, whereas
miR-320 and miR-342-3p and to a lesser extent miR-7*, exhibit a
positive correlation. TCA cycle intermediates including citrate,
succinate, 2-oxoglutarate and fumarate are positively correlated
with miR-143, miR-126-3p, miR-146a, miR-150 and miR-155.
Interestingly, these same miRNAs are inversely correlated with
urinary host-microbial co-metabolites such as p-cresyl glucuro-
nide, p-cresyl sulfate and phenylacetylglycine. In addition to
miR-342-3p and miR-34c*, miR-872*, miR-463*, miR-30e, miR-2183,
miR-1971, miR-150, miR-146a, miR-1188 and miR-93* all correlate
with liver energy metabolism processes, such as glycolysis and
glycogenesis involving glucose, glycogen and lactate.
Altered miR-122 expression levels in plasma and liver tissues are
responsible for metabolic changes post RYGB surgery
RYGB induced the strongest effects on miR-122, as downregula-
tion of miR-122 was observed in both bariatric patients13 and our
rodent model for RYGB, we subsequently focused on investigating
miR-122-mediated metabolic pathways. We ﬁrst conﬁrmed
miR-122 expression levels in both plasma and liver tissue using
Taqman real-time quantitative PCR (Figure 3a). The Pearson
correlation value of the results derived from Taqman low-density
array cards and quantitative PCR is 0.9983 (Po0.0001). Plasma
miR-122 showed a 99% reduction in levels in RYGB-operated rats
compared with SHAM controls, whereas hepatic miR-122 only
showed 30% reduction of expression. We next examined a group
of miR-122 targets, which are involved in key liver metabolic
processes, such as the TCA cycle (Cs, citrate synthase), glucose
transport (Glut1, glucose transporter protein type 1), pentose
phosphate pathway (G6pd, glucose-6-phosphate dehydrogenase),
fatty-acid synthesis (Fasn, fatty-acid synthase), energy sensing
(Prkab1, adenosine monophosphate (AMP)-activated kinase beta 1),
mitochondrial oxidation (Ucp2, uncoupling protein 2), gluco-
neogenesis (G6pc, glucose-6-phosphatase) and glycolysis (Aldoa,
aldolase A). All mRNA targets are bona ﬁde validated except for
the putative targets UCP2 and AMPKβ1. These miR-122 targets in
the liver all exhibited 41.5 fold increase in expression ranging
from 1.53 to 1.91, except for Glut1 and G6pc. Although the
alteration of Glut1 was not signiﬁcant, it showed a clearly
increased trend in the expression (P= 0.1061). G6pc expression, a
validated miR-122 target, is surprisingly reduced 480% in the
RYGB group (Figure 3c). G6pc expression was lowered rather than
elevated in the hepatic tissue, suggesting perhaps regulatory
mechanisms of G6pc other than miR-122 predominate. We then
investigated whether miR-122 can directly modulate these mRNA
targets by manipulating their expression in the hepatocyte-like
B13H cell line (derived from a pancreatic AR42J-B13 cell line
transdifferentiated with dexamethasone as primary hepatocytes
are phenotypically unstable over the required time frame for the
experiment). Transdifferentiation of this pancreatic cell to the
B13H cell derivative, results phenotypically in a liver-like cell
expressing liver-speciﬁc and enriched functional enzymes.14 In
fact, miR-122, believed to be a hepatocyte-speciﬁc miRNA, was
upregulated more than 400-fold during this trans-differentiation
process (Supplementary Figure S5), consistent with the hepatic
phenotype. In B13H cells transfected with miR-122 mimic,
expression of Cs, Glut1, Fasn, Aldoa, G6pd, Prkab1 and Ucp2 were
all reduced (although the last three not signiﬁcantly) in
comparison with controls transfected with scrambled miRNA
mimic (Figure 3d). Consistent with the aforementioned in vivo
ﬁndings, the G6pc expression level was not affected by miR-122 in
the B13H cell line. We concluded that miR-122 directly modulated
Cs, Glut1, Fasn, Aldoa and to a lesser extent, G6pd, Ucp2 and
Prkab1.
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We conﬁrmed these transcriptional effects on protein expres-
sion in the liver tissues of RYGB- and SHAM-operated rats
(Figure 3f). CS, catalyzing the formation of citrate from oxaloace-
tate and acetyl coenzyme A, is a mitochondrial marker and has a
key role in regulating energy generation in TCA cycle and
mitochondrial respiration. We found that RYGB rats exhibited a
twofold increase in CS protein expression (Figure 3g). UCP2
protein level showed a 2.6-fold upregulation in the RYGB animals
(Figure 3h), consistent with the altered mRNA expression level
(1.7-fold upregulation). AMPK acts as an energy switch; in an
Figure 1. Altered circulating microRNAs and targeted signaling pathways. (a) The Roux-en-Y gastric bypass (RYGB) surgery altered the
expression of 14 circulating microRNAs with 3 upregulated (yellow) and 11 downregulated (blue) in the RYGB-operated animals (n= 4)
compared with sham controls (n= 4). P-values are derived from two-tailed t-test. (b) The heat map with two-way clustering shows clear
grouping of RYGB and SHAM animals based on 14 signiﬁcantly altered microRNAs. (c) The predicted pathways that these microRNAs can
target are ranked according to the number of potentially involved microRNAs. P-values represent a statistical overrepresentation or
underrepresentation of the genes in the predicted microRNA target list relative to the reference pathway gene list.
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energy-deﬁcient status (high AMP:ATP; adenosine triphosphate
ratio), AMPK can switch off ATP-consuming biosynthesis path-
ways, such as Fasn in adipocytes, cholesterol synthesis and
gluconeogenesis in the liver, and switch on ATP-producing
catabolic pathways, for example, fatty-acid oxidation and glyco-
lysis in multiple tissues.15 AMPKβ1 units require activation via
phosphorylation.16 Although the non-phosphorylated-AMPKβ1
was downregulated by 2.5 fold, the active phosphorylated-
AMPKβ1 protein was signiﬁcantly upregulated by twofold
(Figures 3i and j).
DISCUSSION
Bariatric surgery has been shown to markedly alter circulating
miRNAs in patients, in particular, downregulation of miR-122 by
94.7%.13 However, the metabolic functions and consequences of
these dysregulated miRNAs have not been clariﬁed or validated to
date. We therefore investigated the correlation of the miRNAome
and metabolites in a bariatric surgical model to elucidate
energetic, microbial and neuronal signaling mechanisms of
disease resolution. The mechanisms of RYGB surgery are complex;
from our study and the work of others; it is apparent that
circulating miRNAs could potentially work as a class of hormone,
so-called miRormone,17 to mediate energy metabolism resulting
in weight loss and potentially reset the brain-food rewarding
system. Decreased plasma levels of miR-342-3p, miR-320, miR-139-
5p and miR-146a observed in our study suggest RYGB surgery
impact on multiple neurodegenerative disease-related pathways.
Patients with Parkinson’s disease commonly experience unin-
tended weight loss18 and factors including reduced food intake
owing to dysphagia, increased resting energy expenditure and
potential peptide hormones, such as ghrelin, could account for the
underlying mechanisms.19 There is increased evidence suggesting
a beneﬁcial effect of bariatric operations on neurodegenerative
disease based on surgical activity on caloric restriction, glycaemic
control and gut hormonal modulation.20 The common miRNA-
targeted pathways between bariatric surgery and Parkinson’s
disease suggest that surgery-induced weight loss may share
certain mechanistic pathways with unintended weight loss in
Parkinson’s disease patients.
MiR-122 is a liver-produced miRNA and its less marked reduced
expression in the liver compared with plasma suggests a
restrained miR-122 release into the blood stream after RYGB
surgery. By antagonizing miR-122 with LNA (locked-nucleic-acid-
modiﬁed oligonucleotide)-anti-miR-122 in diet-induced obese
mice for 6 weeks, a 30% decrease in total cholesterol levels was
achieved without lipid accumulation in the liver and tested
miR-122 mRNA targets were similar to our ﬁndings except for
G6pc, which was upregulated.21 Esau et al.22 demonstrated that
injecting miR-122 antisense oligonucleotide into mice for 5 weeks
results in reduced plasma cholesterol levels, increased hepatic
fatty-acid oxidation, decreased hepatic fatty-acid and cholesterol
synthesis rates; effects that are also seen in primates.23 Following
RYGB surgery, we observed increased glucose transportation,
accelerated glycolysis and inhibited gluconeogenesis in the RYGB
rat model. Glut1, a glucose transporter, was upregulated
consistent with the decreased miR-122 expression in the liver
and increased levels of hepatic glucose and glycogen were
observed, indicating that RYGB promotes glucose transportation
and glycogen synthesis. Our metabolic and miR-122 target
expression data show that RYGB surgery suppresses gluconeo-
genesis and stimulates glycolysis, as evidenced by the
Figure 2. Correlation between miRNome and metabolic proﬁles. The heat map is generated from the Pearson correlation coefﬁcient values
between circulating microRNA expression and metabolite levels using a two-way clustering method. The horizontal axis shows all detectable
circulating microRNAs, whereas the vertical axis exhibits altered plasma, urinary and hepatic metabolites following RYGB. The color bar next to
the metabolites indicates metabolic functions (amino acid metabolism, lipid metabolism and ketone body metabolism, glycolysis and
glycogenolysis, TCA cycles, microbial activity, nucleic acid metabolism, muscle metabolism and vitamin metabolism) of the metabolites.
MicroRNAs, which are signiﬁcantly altered by RYGB surgery, are shown in yellow (upregulated) and blue (downregulated), respectively. SHAM
n= 4, RYGB n= 4. Keys: PAG, phenylacetylglycine; TMAO, trimethyalmine-N-oxide; TCA, tricarboxylic acid.
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downregulation of G6pc and upregulation of Aldoa, together with
elevated concentrations of glycolysis end products including
pyruvate, alanine and lactate in the liver and plasma (Figure 4).
Mencarelli et al.24 have recently investigated the effects of ileal
interposition, where the distal ileum is relocated into the proximal
jejunum, which mimics a partial procedure of RYGB surgery.
Consistent with our results, the hepatic expression of G6pc was
also suppressed in this ileal interposition model. Furthermore,
G6pd was found to be upregulated and this is an indicator for
oxidative activity of the pentose phosphate pathway. It is likely
that G6pd is stimulated by the unbalanced ratio of NADPH/NADP+
(normally 100:1 in the hepatic cytosol) to favor NADPH production.
This unbalanced ratio could be because of the utilization of
NADPH in the liver by reductive biosynthesis, such as lipid
biosynthesis. G6PD expression and enzyme activity have been
reported to be upregulated in the Roux limb of RYGB-operated
rats, as well as Glut1,25 and the authors concluded that the
reprogramming of intestinal glucose, including enhanced baso-
lateral glucose uptake, augmented glycolysis and stimulated
pentose phosphate pathway, could contribute to the glycemic
control after RYGB.
Decreased miR-122 levels induced the upregulation of Cs (CS)
and Ucp2 (UCP2). CS is a well-studied rate-limiting enzyme in the
TCA cycle. Although the metabolic function of UCP2 is still
controversial and varies between various types of tissues, it is
believed to have a pivotal role in obesity, diabetes, metabolic
Figure 3. Expression levels of miR-122 and its targets in vitro and in vivo. The Roux-en-Y gastric bypass results in the altered miR-122 expression
levels in plasma (a) and the liver (b) measured by quantitative PCR. (c) The expression levels of miR-122 mRNA targets, including citrate
synthase (Cs), glucose transporter protein type 1 (Glut1), glucose-6-phosphate dehydrogenase (G6pd), fatty-acid synthase (Fasn), AMP-
activated kinase beta 1 (Prkab1), uncoupling protein 2 (Ucp2), glucose-6-phosphatase (G6pc) and aldolase A (Aldoa), are measured by
quantitative PCR in the liver of RYGB- (n= 8) and SHAM- (n= 5) operated animals. (d) These targets were evaluated in B13H cells transfected
with miR-122 mimic (treatment, n= 4) or scrambled miRNA (control, n= 4) and measured by quantitative PCR. (e) A previous in vivo study by
Elamn et al (Data were extracted from Array Express Experiment No. E-MEXP-1406, n= 5 each group). (f) Immunoblot of the hepatic protein
expression levels of citrate synthase, UCP2, AMPK-beta 1 and phosporylated AMPK-beta 1 in the RYGB- and sham-operated animals.
(g–j) show quantiﬁed protein expressions of citrate synthase, UCP2, AMPK-beta 1 and phospho-AMPK-beta 1, respectively. All data represent
mean± s.e.m. (RYGB, n= 8; SHAM, n= 5), unless otherwise speciﬁed in each ﬁgure. *Po0.05; **Po0.01; ***Po0.001.
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syndrome and several neurodegenerative diseases26,27 Hepatic
UCP2, which uncouples oxidative phosphorylation with ATP
production, is highly associated with oxidative phosphorylation
and fatty-acid oxidation. UCP2 is responsible for proton transpor-
tation from the intermembrane space to the mitochondria matrix
and uncouples proton ﬂux with ATP synthesis. The upregulation of
UCP2 and CS in the liver indicates that the RYGB-operated animals
exhibit higher cellular metabolic activity such as favored fatty-acid
oxidation and increased TCA cycle metabolism, which is further
supported by the decreased levels of urinary TCA cycle
intermediates detected by metabonomic analysis. Furthermore,
UCP2 is a downstream effector of the energy sensor AMPK coded
by the Prkab1 gene. In the present study, we also observed
increased Prkab1 expression followed by upregulated UCP2. After
RYGB, fat stored in adipose tissue is thought to be mobilized and
metabolized in the liver,28 generating increased levels of free fatty
acids, which could result in upregulated UCP2. It has been shown
that increased UCP2 could not only promote the energy
expenditure toward lipid utilization29 and compensate reduction
of reactive oxygen species,30 but also reduce oxidative stress31
and protect mitochondria during fatty-acid β-oxidation.32 This is
consistent with decreased reactive oxygen species reported in
patients after bariatric surgery.33,34 Hence, UCP2 and oxidative
decoupling may contribute to postoperative weight loss. We
observed that fatty-acid synthase (Fasn) also increased following
RYGB surgery. The underlying reason for the increase in Fasn is
unclear, but one possibility is that RYGB extensively affects lipid
metabolism and leads to a restoration of adipose redox balance.
Therefore, further studies should address lipid metabolism during
the re-adjustment period after bariatric surgery.
In conclusion, we have demonstrated that RYGB surgery
signiﬁcantly modiﬁed metabolite and miRNA proﬁles of SD rats,
resulting in substantial weight loss. We have demonstrated that
miR-122 contributed to the control of energy metabolism with
increased glucose transportation, glycolysis, TCA cycle, pentose
phosphate shunt and fatty-acid oxidation and decreased gluco-
neogenesis and ketone body generation (Figure 4), suggesting an
overall increased energy expenditure status. By correlating the
circulating miRNAome and metabolome data, we were able to
generate for the ﬁrst time a comprehensive landscape of the
crosstalk between miRNAs and metabolic pathways that point to a
systemic regulation of processes including multiple axes of energy
metabolism and suggested impact on the gut-brain axis. Follow-
up studies will allow a detailed understanding of miRNAs
responsible for regulating speciﬁc metabolic pathways, and
conversely identifying metabolites capable of regulating the
expression and activity of speciﬁc miRNAs. Our study highlights
the value of transomic modeling and opens up a new window to
further understand fundamental mechanisms associated with
metabolic surgery and potential therapeutic targets for obesity
and diabetes treatment.
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Figure 4. Modulation of metabolic activity by the downregulation of miR-122 following Roux-en-Y gastric bypass surgery. RYGB-induced
metabolic changes in liver, plasma and urine (red and blue oval), metabolic enzymes (red and blue 3D boxes), and metabolic pathways (red
and green ﬂat boxes) are summarized. Keys: 2-OG, 2-oxoglutarate; 6-PGL, 6-phospho-D-glucono-1,5-lactone; AcCoA, Acetyl coenzyme A;
Alodoa, aldolase A; AMP-activated kinase beta 1 (Prkab1, AMPK beta 1), β-D-Fruc-1,6 P2; Cs, citrate synthase; FA, fatty acids; Fasn, fatty-acid
synthase; G6pc, glucose-6-phosphatase; G6pd, glucose-6-phosphate dehydrogenase; GD-3p, glyceraldehydes-3-phosphate; Gln, glutamine;
Glu, glutamate; glucose-6-p, glucose-6-phosphatel; Glut1, glucose transporter protein type 1; HB, D-3-hydroxybutyrate; NADPH/NADP+,
nicotinamide adenine dinucleotide phosphate; OAA, oxaloacetate; PAG, phenylacetylglycine; ROS, reactive oxygen species; suc, succinate; suc-
CoA, succinyl coenzyme A; TCA cycle, tricarboxylic acid cycle; TMAO, trimethylamine-N-oxide; Ucp2, uncoupling protein 2.
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